DrugDev do more trials

SiteStart

Find and Activate Ideal Global Investigators

Finding the right investigators and making their lives easier are universal keys to running successful clinical trials. Our unique combination of technology and investigator relationships ensures you can zoom in on the sites that are right for your study and activate sites faster, thereby shaving months off the protocol feasibility and site selection process while maximizing your chances of success.

Ideal Sites Actively Seeking New Trial Opportunities

At our core, DrugDev is committed to helping investigators do more trials. We provide sponsors and CROs with access to the industry's largest global network of opted-in investigators actively seeking new trial opportunities. With more than 80,000 clinical doctors in 115 countries, the DrugDev Network and our expert Site Identification team will ensure you identify and select the right investigators for your trial.

The DrugDev Network was organically built and grown with investigators who have signed up because they have expressed a sincere desire to work with industry (as opposed to publicly available and unreliable site contact lists) and are motivated to reach your patient enrollment and retention goals.

Our multilingual site engagement team based in London regularly interacts with investigators in their own language to cultivate proprietary relationships and develop a deep understanding of their site and experience. DrugDev customers benefit from these personal relationships to identify investigators with very specific expertise, find research naive investigators with abundant eligible patient pools, gain helpful referrals, and react to rapidly changing geopolitical challenges.

What Makes Our Network Different?

- *80,000 opted-in investigators actively seeking new trial opportunities*
- *115 countries*
- *Over 60% ex-U.S. investigators*
- *Established personal relationships*
- *Access to 400,000 investigators with publicly available information*

Where Are the Investigators in Our Network Located?



1 King Street, London, UK W6 9HR | solutions@drugdev.com | +44 208 741 0918
1170 Devon Park Dr., Suite 300, Wayne, PA 19087 | solutions@drugdev.com | +1 888 650 1860

Improve Protocol Feasibility

According to Tufts, 69% of all protocols require amendments with an average cost of $450,000 or more. By leveraging our established relationships with global investigators, DrugDev significantly reduces the risk of costly protocol amendments and other unforeseen obstacles in trial design by soliciting feedback from experts early in the startup process. Such feedback may reveal too restrictive inclusion/exclusion criteria, insufficient patient pool demographics or that the study drug is not considered standard of care in their country. By collaborating with investigators from the very start you will engage sites, spend your time acting on feasibility data rather than collecting it, and ultimately reduce protocol amendments and delays.

Contract with Sites Around the World

In a global DrugDev survey, 46% of sites reported that completing contracts and regulatory documents is a major obstacle to trial participation. A prolonged and inefficient process leads to investigator frustration and dissatisfaction before the trial begins, while milestones such as drug shipments, IRB approval and randomization can't start until the process is complete.

Using our technology platform and legal resources in more than 60 countries, DrugDev creates, negotiates and manages clinical trial agreements (CTAs) from draft through execution with full transparency. Our automated system tracks projects and site information, key negotiated terms stratified by budget, country-specific tax regulations, contract clauses, informed consent redlined agreements with version control, and negotiation status. This ensures you remain in control of the entire contract lifecycle including site budgets, CTAs and financial disclosure forms.

Customers also benefit from access to IMS Health GrantPlan and our comprehensive proprietary database of procedures and costs in order to develop a realistic and fair investigator grant budget and payment schedule. As a result, DrugDev helps streamline timelines, improve investigator satisfaction, and alleviate the burden of your legal team so they can focus on more strategic risk mitigation priorities than chasing after busy site personnel.

Collecting Essential Regulatory Documents

Addressing today's increasingly complex compliance requirements using manual processes is time-consuming, error-prone, and risky for your organization. Concerns regarding a lack of quality control in regulatory and financial disclosure documentation is especially important given the Sunshine Act, as discrepancies with physician self-reported financial data could increase your financial and regulatory risk.

With DrugDev, it is easy to improve the effectiveness of feasibility and site selection, shorten study timelines and eliminate the volatile resourcing and IT challenges associated with supporting these tasks. We maintain a robust quality management system that features multi-tier QC review for essential regulatory documents, up-to-date standard operating procedures, training programs, periodic audits, and managerial governance to ensure compliance with financial standards and ICH Good Clinical Practice regulations.

By partnering with DrugDev, sponsors and CROs are able to collect and manage essential regulatory documents within a precise, efficient and transparent technology platform to comply with intricate global regulations and enable sites to begin working toward achieving key randomization objectives faster.

Improve Site Selection and Startup

Email solutions@drugdev.com to learn more about the DrugDev Network and our activation services for trial feasibility, contracting and essential reg docs.

1 King Street, London, UK W6 9HR | solutions@drugdev.com | +44 208 741 0918
1170 Devon Park Dr., Suite 300, Wayne, PA 19087 | solutions@drugdev.com | +1 888 650 1860